Evaxion A/S’s (EVAX) Sell (D-) Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (d-) rating on shares of Evaxion A/S (NASDAQ:EVAX) in a research note released on Tuesday,Weiss Ratings reports.

Other analysts have also issued research reports about the stock. HC Wainwright boosted their price target on shares of Evaxion A/S from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Thursday, September 25th. Wall Street Zen upgraded shares of Evaxion A/S to a “hold” rating in a research note on Friday, June 27th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $11.00.

Evaxion A/S Stock Performance

Shares of EVAX stock opened at $9.60 on Tuesday. The firm has a market capitalization of $13.44 million, a PE ratio of -7.27 and a beta of 0.23. The firm has a fifty day simple moving average of $3.94 and a two-hundred day simple moving average of $2.76. The company has a current ratio of 3.42, a quick ratio of 3.42 and a debt-to-equity ratio of 1.73. Evaxion A/S has a 12 month low of $1.20 and a 12 month high of $15.50.

Evaxion A/S (NASDAQ:EVAX) last announced its quarterly earnings results on Thursday, August 14th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.26). The business had revenue of $0.04 million for the quarter. Analysts forecast that Evaxion A/S will post -0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Evaxion A/S

An institutional investor recently raised its position in Evaxion A/S stock. Merck & Co. Inc. grew its position in shares of Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) by 123.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,214,126 shares of the company’s stock after acquiring an additional 671,847 shares during the quarter. Evaxion A/S accounts for approximately 1.4% of Merck & Co. Inc.’s portfolio, making the stock its 6th largest holding. Merck & Co. Inc. owned about 86.54% of Evaxion A/S worth $2,246,000 at the end of the most recent reporting period. 11.04% of the stock is owned by institutional investors and hedge funds.

Evaxion A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.